STRATASYS LTD.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED
MARCH 31, 2025
(UNAUDITED)
1
STRATASYS LTD.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited)
INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2025
(UNAUDITED)
2
STRATASYS LTD.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Balance Sheets
|
|
|
|
|
(U.S. $ in thousands, except share data)
|
|
|
|
|
|
|
March 31, 2025
|
|
December 31, 2024
|
ASSETS
|
|
|
|
|
Current assets
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
70,061
|
|
|
$
|
70,200
|
|
Short-term bank deposits
|
|
80,000
|
|
|
80,500
|
|
Accounts receivable, net of allowance for credit losses of $3,048 and $3,058 as of March 31, 2025 and December 31, 2024, respectively
|
|
156,150
|
|
|
152,979
|
|
Inventories
|
|
169,881
|
|
|
179,809
|
|
Prepaid expenses
|
|
10,616
|
|
|
7,630
|
|
Other current assets
|
|
20,923
|
|
|
21,843
|
|
|
|
|
|
|
Total current assets
|
|
507,631
|
|
|
512,961
|
|
Non-current assets
|
|
|
|
|
Property, plant and equipment, net
|
|
186,866
|
|
|
184,379
|
|
Goodwill
|
|
99,463
|
|
|
99,082
|
|
Other intangible assets, net
|
|
101,619
|
|
|
106,253
|
|
Operating lease right-of-use assets
|
|
31,097
|
|
|
32,169
|
|
Long-term investments
|
|
81,518
|
|
|
80,205
|
|
Other non-current assets
|
|
14,950
|
|
|
14,697
|
|
|
|
|
|
|
Total non-current assets
|
|
515,513
|
|
|
516,785
|
|
|
|
|
|
|
Total assets
|
|
$
|
1,023,144
|
|
|
$
|
1,029,746
|
|
|
|
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
Current liabilities
|
|
|
|
|
Accounts payable
|
|
$
|
38,032
|
|
|
$
|
44,977
|
|
Accrued expenses and other current liabilities
|
|
36,310
|
|
|
39,749
|
|
Accrued compensation and related benefits
|
|
34,905
|
|
|
29,206
|
|
Deferred revenues - short-term
|
|
51,897
|
|
|
46,347
|
|
Operating lease liabilities - short-term
|
|
6,921
|
|
|
6,935
|
|
|
|
|
|
|
Total current liabilities
|
|
168,065
|
|
|
167,214
|
|
Non-current liabilities
|
|
|
|
|
Deferred revenues - long-term
|
|
20,138
|
|
|
19,057
|
|
Deferred income taxes
|
|
459
|
|
|
507
|
|
Operating lease liabilities - long-term
|
|
24,363
|
|
|
25,155
|
|
Contingent consideration - long-term
|
|
5,089
|
|
|
4,933
|
|
Other non-current liabilities
|
|
20,189
|
|
|
19,889
|
|
|
|
|
|
|
Total non-current liabilities
|
|
70,238
|
|
|
69,541
|
|
|
|
|
|
|
Total liabilities
|
|
$
|
238,303
|
|
|
$
|
236,755
|
|
|
|
|
|
|
Contingencies (see note 12)
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
Ordinary shares, NIS 0.01 nominal value, authorized 180,000 shares; 72,657 shares and 71,982 shares issued at March 31, 2025 and December 31, 2024, respectively; 72,391 shares and 71,716 shares outstanding at March 31, 2025 and December 31, 2024, respectively
|
|
$
|
203
|
|
|
$
|
202
|
|
Treasury shares at cost, 266 shares at March 31, 2025 and December 31, 2024
|
|
(1,995)
|
|
|
(1,995)
|
|
Additional paid-in capital
|
|
3,129,236
|
|
|
3,123,024
|
|
Accumulated other comprehensive loss
|
|
(9,340)
|
|
|
(8,031)
|
|
Accumulated deficit
|
|
(2,333,263)
|
|
|
(2,320,209)
|
|
Total equity
|
|
784,841
|
|
|
792,991
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
1,023,144
|
|
|
$
|
1,029,746
|
|
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
3
STRATASYS LTD.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Operations and Comprehensive Loss
|
|
|
|
|
(U.S. $ in thousands, except per share data)
|
|
Three Months Ended March 31,
|
|
|
2025
|
|
2024
|
|
|
|
|
|
Revenues
|
|
|
|
|
Products
|
|
$
|
93,795
|
|
|
$
|
99,196
|
|
Services
|
|
42,251
|
|
|
44,854
|
|
|
|
136,046
|
|
|
144,050
|
|
Cost of revenues
|
|
|
|
|
Products
|
|
47,268
|
|
|
49,757
|
|
Services
|
|
28,539
|
|
|
30,396
|
|
|
|
75,807
|
|
|
80,153
|
|
|
|
|
|
|
Gross profit
|
|
60,239
|
|
|
63,897
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
Research and development, net
|
|
18,792
|
|
|
23,977
|
|
Selling, general and administrative
|
|
53,851
|
|
|
64,373
|
|
|
|
72,643
|
|
|
88,350
|
|
|
|
|
|
|
Operating loss
|
|
(12,404)
|
|
|
(24,453)
|
|
|
|
|
|
|
Financial income, net
|
|
1,473
|
|
|
1,217
|
|
|
|
|
|
|
Loss before income taxes
|
|
(10,931)
|
|
|
(23,236)
|
|
|
|
|
|
|
Income tax expenses
|
|
455
|
|
|
716
|
|
|
|
|
|
|
Share in losses of associated companies
|
|
1,668
|
|
|
2,031
|
|
|
|
|
|
|
Net loss
|
|
$
|
(13,054)
|
|
|
$
|
(25,983)
|
|
|
|
|
|
|
Net loss per share - basic and diluted
|
|
$
|
(0.18)
|
|
|
$
|
(0.37)
|
|
|
|
|
|
|
Weighted average ordinary shares outstanding - basic and diluted
|
|
71,967
|
|
|
69,993
|
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
Net loss
|
|
(13,054)
|
|
|
(25,983)
|
|
Other comprehensive loss, net of tax:
|
|
|
|
|
Foreign currency translation adjustments
|
|
1,726
|
|
|
(2,186)
|
|
Unrealized gains (losses) on derivatives designated as cash flow hedges, net
|
|
(3,035)
|
|
|
682
|
|
Other comprehensive loss, net of tax
|
|
(1,309)
|
|
|
(1,504)
|
|
Comprehensive loss
|
|
$
|
(14,363)
|
|
|
$
|
(27,487)
|
|
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
4
STRATASYS LTD.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Changes in Equity
|
|
|
|
|
|
|
|
|
(U.S. $ in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2025
|
Ordinary Shares
|
|
Treasury Shares
|
|
|
|
|
|
|
|
|
|
Number of shares
|
|
Par Value
|
|
Number of shares
|
|
Par Value
|
|
Additional Paid-In Capital
|
|
Accumulated Deficit
|
|
Accumulated Other Comprehensive Loss
|
|
Total Equity
|
Balances as of December 31, 2024
|
71,982
|
|
|
$
|
202
|
|
|
(266)
|
|
|
$
|
(1,995)
|
|
|
$
|
3,123,024
|
|
|
$
|
(2,320,209)
|
|
|
$
|
(8,031)
|
|
|
$
|
792,991
|
|
Issuance of shares in connection with stock-based compensation plans
|
675
|
|
|
1
|
|
|
-
|
|
|
-
|
|
|
(1)
|
|
|
-
|
|
|
-
|
|
|
-
|
|
Stock-based compensation
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
6,213
|
|
|
-
|
|
|
-
|
|
|
6,213
|
|
Comprehensive loss
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(13,054)
|
|
|
(1,309)
|
|
|
(14,363)
|
|
Balances as of March 31, 2025
|
72,657
|
|
|
$
|
203
|
|
|
(266)
|
|
|
$
|
(1,995)
|
|
|
$
|
3,129,236
|
|
|
$
|
(2,333,263)
|
|
|
$
|
(9,340)
|
|
|
$
|
784,841
|
|
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Changes in Equity
|
|
|
|
|
|
|
|
|
(U.S. $ in thousands)
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2024
|
Ordinary Shares
|
|
|
|
|
|
|
|
|
|
Number of shares
|
|
Par Value
|
|
Additional Paid-In Capital
|
|
Accumulated Deficit
|
|
Accumulated Other Comprehensive Loss
|
|
Total Equity
|
Balances as of December 31, 2023
|
69,656
|
|
|
$
|
195
|
|
|
$
|
3,091,649
|
|
|
$
|
(2,199,926)
|
|
|
$
|
(7,079)
|
|
|
$
|
884,839
|
|
Issuance of shares in connection with stock-based compensation plans
|
784
|
|
|
2
|
|
|
147
|
|
|
-
|
|
|
-
|
|
|
149
|
|
Stock-based compensation
|
-
|
|
|
-
|
|
|
8,649
|
|
|
-
|
|
|
-
|
|
|
8,649
|
|
Comprehensive loss
|
-
|
|
|
-
|
|
|
-
|
|
|
(25,983)
|
|
|
(1,504)
|
|
|
(27,487)
|
|
Balances as of March 31, 2024
|
70,440
|
|
|
$
|
197
|
|
|
$
|
3,100,445
|
|
|
$
|
(2,225,909)
|
|
|
$
|
(8,583)
|
|
|
$
|
866,150
|
|
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
5
STRATASYS LTD.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Cash Flows
|
|
|
|
U.S. $ in thousands
|
Three Months Ended March 31,
|
|
2025
|
|
2024
|
Cash flows from operating activities
|
|
|
|
Net loss
|
$
|
(13,054)
|
|
|
$
|
(25,983)
|
|
Adjustments to reconcile net loss to net cash provided by operating activities:
|
|
|
|
Depreciation and amortization
|
10,771
|
|
|
12,266
|
|
Stock-based compensation
|
6,213
|
|
|
8,649
|
|
Foreign currency transaction (gain) loss
|
(2,288)
|
|
|
2,054
|
|
Share in losses of associated companies
|
1,668
|
|
|
2,031
|
|
Revaluation of investments
|
180
|
|
|
1,747
|
|
Revaluation of contingent consideration
|
506
|
|
|
511
|
|
Deferred income taxes, net and uncertain tax positions
|
123
|
|
|
183
|
|
Other non-cash items, net
|
21
|
|
|
493
|
|
|
|
|
|
Change in cash attributable to changes in operating assets and liabilities:
|
|
|
|
Accounts receivable, net
|
(4,772)
|
|
|
15,461
|
|
Inventories
|
9,945
|
|
|
897
|
|
Other current assets and prepaid expenses
|
(2,077)
|
|
|
1,872
|
|
Other non-current assets
|
1,486
|
|
|
3,148
|
|
Accounts payable
|
(9,329)
|
|
|
(9,507)
|
|
Other current liabilities
|
(80)
|
|
|
(115)
|
|
Deferred revenues
|
6,127
|
|
|
(2,202)
|
|
Other non-current liabilities
|
(898)
|
|
|
(4,165)
|
|
Net cash provided by operating activities
|
4,542
|
|
|
7,340
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
Purchase of property and equipment
|
(3,753)
|
|
|
(2,329)
|
|
Investments in short-term bank deposits
|
(40,000)
|
|
|
(10,000)
|
|
Proceeds from short-term bank deposits
|
40,500
|
|
|
20,000
|
|
Investments in unconsolidated entities
|
(330)
|
|
|
(4,993)
|
|
Purchase of intangible assets
|
(485)
|
|
|
(658)
|
|
Other investing activities
|
(20)
|
|
|
(120)
|
|
Net cash provided by (used in) investing activities
|
(4,088)
|
|
|
1,900
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
Proceeds from exercise of stock options
|
-
|
|
|
149
|
|
Payment of contingent consideration
|
(100)
|
|
|
(430)
|
|
Other financing activities
|
300
|
|
|
465
|
|
Net cash provided by financing activities
|
200
|
|
|
184
|
|
|
|
|
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
(841)
|
|
|
(925)
|
|
|
|
|
|
Net change in cash, cash equivalents and restricted cash
|
(187)
|
|
|
8,499
|
|
Cash, cash equivalents and restricted cash, beginning of period
|
71,076
|
|
|
82,864
|
|
Cash, cash equivalents and restricted cash, end of period
|
$
|
70,889
|
|
|
$
|
91,363
|
|
|
|
|
|
Supplemental disclosures of cash flow information:
|
|
|
|
Transfer of inventories to fixed assets
|
1,701
|
|
|
545
|
|
Transfer of fixed assets to inventories
|
-
|
|
|
4,692
|
|
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:
|
|
|
|
Cash and cash equivalents
|
70,061
|
|
|
91,089
|
|
Restricted cash included in other current assets
|
828
|
|
|
274
|
|
Total cash, cash equivalents and restricted cash shown in the consolidated statement of cash flows
|
$
|
70,889
|
|
|
$
|
91,363
|
|
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
6
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Note 1. Business Description and Basis of Presentation
Stratasys Ltd. (collectively with its subsidiaries, the "Company" or "Stratasys") is a global leader in connected, polymer-based 3D printing solutions, across the entire manufacturing value chain. The Company leverages its competitive advantages, which include a broad set of best-in-class 3D printing platforms, software, a materials and technology partner ecosystem, innovative leadership, and global GTM infrastructure, in order to position itself to capture share in a significant and growing global marketplace, with a focus on manufacturing, which the Company views as having the largest and fastest growing total addressable market. The Company's approximately 2,300 granted and pending additive technology patents to date have been used to create models, prototypes, manufacturing tools, and production parts for a multitude of industries including aerospace, automotive, transportation, healthcare, consumer products, dental, medical, fashion and education. Stratasys' products and comprehensive solutions improve product quality, development time, cost, time-to-market and patient care. The Company's 3D ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production.
The condensed consolidated interim financial information herein is unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in the opinion of management, necessary for a fair statement of results for the interim period. The condensed consolidated interim financial statements include the accounts of Stratasys Ltd. and its subsidiaries. All intercompany accounts and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated in consolidation.
The Company's financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP"), which require the Company to make estimates based on assumptions about current and, for some estimates, future economic and market conditions which affect reported amounts and related disclosures in its financial statements. Although the Company's current estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from the Company's expectations, which could materially affect the Company's results of operations and financial position.
In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these financial statements, Israel's war on various fronts is ongoing and continues to evolve. One of the Company's global headquarters and one of its manufacturing facilities are located in Israel. As of the publication date of these financial statements, the Company's activities in Israel remain largely unaffected by the war. During the three months ended March 31, 2025, the impact of the war on the Company's results of operations and financial condition was limited, but such impact may change, and could be significant, as a result of the further continuation, escalation or expansion of the war. The Company continues to maintain business continuity plans backed by its inventory levels located outside of Israel.
In addition to Israel's multi-front war, a number of global developments that have been impacting, and may continue to impact, macroeconomic conditions also may affect the accounting estimates and assumptions that underlie the Company's financial statements, including, most prominently: the manner and extent (if at all) to which new tariffs slow economic growth and impact the industries into which the Company sells its products; the degree to which inflation remains moderate; whether and when interest rate cuts are implemented by central banks, whether tight credit markets are loosened; whether capital markets rise once again; and whether global supply chains fully recover. As a result of those uncertainties, the accounting estimates and assumptions underlying these consolidated financial statements may change over time. Such changes could have an additional impact on the Company's long-lived asset and intangible asset valuation, and the Company's allowance for expected credit losses. These financial statements reflect the effects of global developments based upon Stratasys' management's estimates and assumptions utilizing the most currently available information.
The results of operations for the three months ended, March 31, 2025 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain financial information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. The reader is referred to the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on March 6, 2025 as part of the Company's Annual Report on Form 20-F for such year.
Note 2. New Accounting Pronouncements
Recently issued accounting pronouncements, not yet adopted
In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.
In November 2024, the FASB issued ASU 2024-03 "Income Statement: Reporting Comprehensive Income- Expense Disaggregation Disclosures," which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.
7
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Note 3. Certain Transactions
MakerBot and Ultimaker transaction ("Ultimaker")
On August 31, 2022, Stratasys completed the merger of MakerBot (previously, a wholly-owned subsidiary) with Ultimaker, which together formed a new entity under the name Ultimaker.
The Company accounts for its investment in the combined company Ultimaker according to the equity method in accordance with ASC Topic 323, as it has retained the ability to exercise significant influence but does not control the new entity. The Company recognized an equity method investment in a total amount of $105.6 million comprised of the assumed fair value of the MakerBot shares and additional amount invested in cash by the Company, representing a share of 46.5% in the new entity.
On March 22, 2024, Ultimaker's shareholders agreed to provide it with additional funding of $8.0 million in cash, out of which $4.5 million was funded by the Company.
During 2024, Ultimaker experienced an improvement in its operating results. However, market conditions remained challenging, especially in the market segment of Ultimaker, with significant competition, resulting in actual revenue that was lower than under prior expectations. The Company considered such events as indicators of potential impairment and accordingly performed an impairment analysis for its investment in Ultimaker. Based on such valuation, the fair value of the investment was estimated below its carrying amount and such reduction in fair value was determined to be other than temporary.
Accordingly, the Company recorded an impairment charge in an amount of $30.1 million, which was recorded in share in losses of associated companies in the Consolidated Statements of Operations and Comprehensive Loss. Management's cash flow projections for the fair value of the Company's investment in Ultimaker are based on significant judgments and assumptions relating to the cash flow projections, future growth and future profitability. Actual results could differ from those estimates, and such differences could be material and may result in other than temporary reduction in fair value, which could lead to additional impairments in the carrying value of the Ultimaker investment.
As of March 31, 2025 and December 31, 2024 the Company's equity investment in Ultimaker amounted to $37.4 million and $39.1 million, respectively, which represents the Company's investment in Ultimaker, net of the Company's share in Ultimaker's net losses. The Company's share in losses of Ultimaker for the three-month periods ended March 31, 2025 and 2024 was approximately $1.7 million and $1.9 million, respectively.
Other long-term investments
In addition to the investment in Ultimaker, other investments included under Long-term investments represent investments in non-marketable equity securities and convertible notes of several companies without readily determinable fair value in which the Company does not have a controlling interest or significant influence. One entity from this group became public during the first quarter of 2021 and accordingly the investment is now treated as a marketable equity investment. During the three months ended March 31, 2025 and during 2024, the Company invested a total of $4.1 million and $13.8 million, respectively, in non-marketable equity securities and convertible notes of several companies. As of March 31, 2025 and December 31, 2024, the total amount invested by the Company in other long-term investments was $43.4 million and $41.1 million, respectively.
8
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Note 4. Revenues
Disaggregation of Revenues
The following table presents the Company's revenues disaggregated by geographical region (based on the Company's customers' locations) and revenue type for the three months ended, March 31, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
2025
|
|
2024
|
|
(U.S. $ in thousands)
|
Americas*
|
|
|
|
Systems
|
$
|
16,541
|
|
|
$
|
17,993
|
|
Consumables
|
34,181
|
|
|
35,542
|
|
Service
|
30,706
|
|
|
33,273
|
|
Total Americas
|
81,428
|
|
|
86,808
|
|
|
|
|
|
EMEA
|
|
|
|
Systems
|
10,022
|
|
|
9,723
|
|
Consumables
|
19,060
|
|
|
21,170
|
|
Service
|
7,613
|
|
|
7,580
|
|
Total EMEA
|
36,695
|
|
|
38,473
|
|
|
|
|
|
Asia Pacific
|
|
|
|
Systems
|
4,609
|
|
|
5,169
|
|
Consumables
|
9,382
|
|
|
9,599
|
|
Service
|
3,932
|
|
|
4,001
|
|
Total Asia Pacific
|
17,923
|
|
|
18,769
|
|
|
|
|
|
Total Revenues
|
$
|
136,046
|
|
|
$
|
144,050
|
|
*Revenues in the United States for the three months ended, March 31, 2025 and 2024 amounted to $76.8 million and $81.7 million, respectively, and are included under the Americas region in the above table.
9
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
The following table presents the Company's revenues disaggregated based on the timing of revenue recognition (at a specific point in time or over the course of time) for the three months ended, March 31, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
2025
|
|
2024
|
|
(U.S. $ in thousands)
|
Revenues recognized in point in time from:
|
|
|
|
Products
|
$
|
93,795
|
|
|
$
|
99,196
|
|
Services
|
12,615
|
|
|
13,773
|
|
Total revenues recognized in point in time
|
106,410
|
|
|
112,969
|
|
|
|
|
|
Revenues recognized over time from:
|
|
|
|
Services
|
29,636
|
|
|
31,081
|
|
Total revenues recognized over time
|
29,636
|
|
|
31,081
|
|
|
|
|
|
Total Revenues
|
$
|
136,046
|
|
|
$
|
144,050
|
|
Contract Assets and Contract Liabilities
Contract assets are recorded when the Company's right to consideration is conditioned on constraints other than the passage of time. The Company had no material contract assets as of March 31, 2025 and December 31, 2024.
Contract liabilities include advance payments and billings in excess of revenue recognized, which are primarily related to advanced billings for service type warranty. Contract liabilities are presented under deferred revenue. The Company's deferred revenue as of March 31, 2025 and December 31, 2024 was as follows:
|
|
|
|
|
|
|
|
|
|
March 31,
|
December 31,
|
|
2025
|
2024
|
|
U.S. $ in thousands
|
Deferred revenue *
|
$
|
72,035
|
|
$
|
65,404
|
|
*Includes $20.1 million and $19.1 million under long-term deferred revenue in the Company's consolidated balance sheets as of March 31, 2025 and December 31, 2024, respectively.
Revenue recognized in 2025 that was included in deferred revenue balance as of December 31, 2024 was $15.7 million for the three months ended, March 31, 2025.
10
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Remaining Performance Obligations
Remaining Performance Obligations ("RPO") represent contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of March 31, 2025, the total RPO amounted to $93.4 million. The Company expects to recognize $62.7 million of this RPO during the next 12 months, $14.7 million over the subsequent 12 months and the remaining $16.0 million thereafter.
Incremental Costs of Obtaining a Contract
Sales commissions earned mainly by the Company's sales agents are considered incremental costs of obtaining a contract with a customer, as the Company expects the benefit of those commissions to be longer than one year. The majority of the sales commissions are not subject to capitalization, as the commission expense is recognized as the related revenue is recognized. Sales commissions for initial contracts related to the service type warranty are deferred and then amortized on a straight-line basis over the expected customer relationship period if the Company expects to recover those costs. Amortization expense is included in selling, general and administrative expenses in the consolidated statements of operations. As of March 31, 2025 and December 31, 2024, the deferred commissions amounted to $9.9 million and $10.3 million, respectively.
11
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Note 5. Inventories
Inventories consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2025
|
|
December 31, 2024
|
|
|
U.S. $ in thousands
|
Finished goods
|
|
$
|
83,366
|
|
|
$
|
90,702
|
|
Work-in-process
|
|
8,994
|
|
|
7,491
|
|
Raw materials
|
|
77,521
|
|
|
81,616
|
|
|
|
$
|
169,881
|
|
|
$
|
179,809
|
|
Note 6. Goodwill and Other Intangible Assets
Goodwill
Changes in the carrying amount of the Company's goodwill during the three months ended March 31, 2025 were as follows:
|
|
|
|
|
|
|
|
|
|
|
U.S. $ in thousands
|
Goodwill as of January 1, 2025
|
|
$
|
99,082
|
|
Currency translation adjustments
|
|
381
|
|
Goodwill as of March 31, 2025
|
|
$
|
99,463
|
|
Other Intangible Assets
Other intangible assets consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2025
|
December 31, 2024
|
|
|
Carrying Amount, net of Impairment
|
Accumulated Amortization
|
Net book value
|
Carrying Amount, net of Impairment
|
Accumulated Amortization
|
Net book value
|
|
|
U.S. $ in thousands
|
Developed technology
|
|
$
|
403,213
|
|
$
|
(322,846)
|
|
$
|
80,367
|
|
$
|
402,976
|
|
$
|
(318,312)
|
|
$
|
84,664
|
|
Patents
|
|
22,452
|
|
(12,152)
|
|
10,300
|
|
21,902
|
|
(11,726)
|
|
10,176
|
|
Trademarks and trade names
|
|
22,201
|
|
(18,218)
|
|
3,983
|
|
22,149
|
|
(17,957)
|
|
4,192
|
|
Customer relationships
|
|
102,721
|
|
(95,752)
|
|
6,969
|
|
102,560
|
|
(95,339)
|
|
7,221
|
|
Capitalized software development costs
|
|
3,117
|
|
(3,117)
|
|
-
|
|
3,117
|
|
(3,117)
|
|
-
|
|
|
|
$
|
553,704
|
|
$
|
(452,085)
|
|
$
|
101,619
|
|
$
|
552,704
|
|
$
|
(446,451)
|
|
$
|
106,253
|
|
Amortization expenses relating to intangible assets for the three-month periods ended March 31, 2025 and 2024 were approximately $5.4 million and $6.9 million, respectively.
12
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
As of March 31, 2025, the estimated amortization expenses relating to intangible assets for each of the following future periods were as follows:
|
|
|
|
|
|
|
|
|
|
|
Estimated amortization expenses
|
|
|
U.S. $ in thousands
|
Remaining 9 months of 2025
|
|
$
|
16,127
|
|
2026
|
|
21,451
|
2027
|
|
20,531
|
2028
|
|
16,432
|
2029
|
|
10,910
|
2030 and thereafter
|
|
16,168
|
Total
|
|
$
|
101,619
|
|
Note 7. Net Loss Per Share
The following table presents the numerator and denominator of the basic and diluted net loss per share computations for the three months ended, March 31, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
2025
|
|
2024
|
|
|
U.S. $ in thousands, except per share amounts
|
Numerator:
|
|
|
|
|
Net loss for basic and diluted net loss per share
|
|
$
|
(13,054)
|
|
|
$
|
(25,983)
|
|
Denominator:
|
|
|
|
|
Weighted average shares, net of treasury shares - for basic and diluted net loss per share
|
|
71,967
|
|
|
69,993
|
|
|
|
|
|
|
Net loss per share
|
|
|
|
|
Basic and diluted
|
|
$
|
(0.18)
|
|
|
$
|
(0.37)
|
|
The computation of diluted net loss per share excluded share awards of 2.9 million shares and 2.3 million shares for the three months ended March 31, 2025 and 2024, respectively, because the inclusion of those shares would have had an anti-dilutive effect on the diluted net loss per share.
Note 8. Income Taxes
The Company had income tax expenses of $0.5 million for the three-month period ended March 31, 2025, compared to income tax expenses of $0.7 million for the three-month period ended March 31, 2024. The Company's effective tax rate as of March 31, 2025, was primarily impacted by the geographic mix of its earnings and losses, movements in its valuation allowance and changes in its uncertain tax positions.
13
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Note 9. Fair Value Measurements
The following table summarizes the Company's financial assets and liabilities that are carried at fair value on a recurring basis, in its consolidated balance sheets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2025
|
|
December 31, 2024
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
|
(U.S. $ in thousands)
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange forward contracts not designated as hedging instruments
|
|
$
|
-
|
|
|
$
|
110
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
71
|
|
|
$
|
-
|
|
Foreign exchange forward contracts designated as hedging instruments
|
|
-
|
|
|
1,294
|
|
|
-
|
|
|
-
|
|
|
4,005
|
|
|
-
|
|
Convertible notes
|
|
-
|
|
|
-
|
|
|
11,525
|
|
|
-
|
|
|
-
|
|
|
10,486
|
|
Marketable securities
|
|
416
|
|
|
-
|
|
|
-
|
|
|
596
|
|
|
-
|
|
|
-
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange forward contracts not designated as hedging instruments
|
|
-
|
|
|
(63)
|
|
|
-
|
|
|
-
|
|
|
(21)
|
|
|
-
|
|
Foreign exchange forward contracts designated as hedging instruments
|
|
-
|
|
|
(70)
|
|
|
-
|
|
|
-
|
|
|
(3)
|
|
|
-
|
|
Contingent consideration*
|
|
-
|
|
|
-
|
|
|
(13,099)
|
|
|
-
|
|
|
-
|
|
|
(12,694)
|
|
|
|
$
|
416
|
|
|
$
|
1,271
|
|
|
$
|
(1,574)
|
|
|
$
|
596
|
|
|
$
|
4,052
|
|
|
$
|
(2,208)
|
|
*Includes $8.0 million and $7.8 million under accrued expenses and other current liabilities in the Company's consolidated balance sheets as of March 31, 2025 and December 31, 2024, respectively.
The Company's foreign exchange forward contracts are classified as Level 2, as they are not actively traded and are valued using pricing models that use observable market inputs, including interest rate curves and both forward and spot prices for currencies (Level 2 inputs).
Contingent consideration represents liabilities recorded at fair value in connection with acquisitions, and thus represents a Level 3 measurement within the fair value hierarchy (refer to Note 3).
Other financial instruments consist mainly of cash and cash equivalents, short-term deposits, current and non-current receivables, accounts payable and other current liabilities. The fair value of these financial instruments approximates their carrying values.
14
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Note 10. Derivative instruments and hedging activities
Since the Company conducts its operations globally, it is exposed to global market risks and to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign currency exchange rates. The Company enters into transactions involving foreign currency exchange derivative financial instruments. The Company manages its foreign currency exposures on a consolidated basis, which allows the Company to net exposures and take advantage of any natural hedging. The transactions are designed to manage the Company's net exposure to foreign currency exchange rates and to reduce the volatility of earnings and cash flows associated with changes in foreign currency exchange rates. The Company does not enter into derivative transactions for trading purposes.
The Company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities and forecasted transactions denominated in the New Israeli Shekel ("NIS"), Euro, British Pound, Korean Won, Chinese Yuan and the Japanese Yen. The gains and losses on the hedging instruments partially offset losses and gains on the hedged items. Financial markets and currency volatility may limit the Company's ability to hedge these exposures. These contracts mature through December 2025.
The following table summarizes the consolidated balance sheets classification and fair values of the Company's derivative instruments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value
|
|
Notional Amount
|
|
Balance sheet location
|
|
March 31, 2025
|
|
December 31, 2024
|
|
March 31, 2025
|
|
December 31, 2024
|
|
|
|
U.S. $ in thousands
|
Assets derivatives - Foreign exchange contracts, not designated as hedging instruments
|
Other current assets
|
|
$
|
110
|
|
|
$
|
71
|
|
|
$
|
75,880
|
|
|
$
|
29,244
|
|
Assets derivatives - Foreign exchange contracts, designated as cash flow hedge
|
Other current assets
|
|
1,294
|
|
|
4,005
|
|
|
96,204
|
|
|
89,414
|
|
Liability derivatives - Foreign exchange contracts, not designated as hedging instruments
|
Accrued expenses and other current liabilities
|
|
(63)
|
|
|
(21)
|
|
|
24,282
|
|
|
82,818
|
|
Liability derivatives - Foreign exchange contracts, designated as cash flow hedge
|
Accrued expenses and other current liabilities
|
|
(70)
|
|
|
(3)
|
|
|
5,322
|
|
|
5,687
|
|
|
|
|
$
|
1,271
|
|
|
$
|
4,052
|
|
|
$
|
201,688
|
|
|
$
|
207,163
|
|
Foreign exchange contracts not designated as hedging instruments
As of March 31, 2025, the notional amounts of the Company's outstanding exchange forward contracts, not designated as hedging instruments, were $100.2 million, and were used to reduce foreign currency exposures of the Euro, New Israeli Shekel (the "NIS"), British Pound, Japanese Yen, Korean Won and Chinese Yuan. With respect to such derivatives, a loss of $2.5 million and a gain of $1.3 million were recognized under financial income, net for the three-month periods ended March 31, 2025 and 2024, respectively. Such gains and losses partially offset the revaluation losses of the balance sheet items which are also recognized under financial income, net.
15
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Cash Flow Hedging - Hedges of Forecasted Foreign Currency Payroll and other operating expenses
As of March 31, 2025, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of $45.4 million into NIS. The Company uses short-term cash flow hedge contracts to reduce its exposure to variability in expected future cash flows resulting mainly from payroll costs denominated in New Israeli Shekels. The changes in fair value of those contracts are included in the Company's accumulated other comprehensive loss.
Cash Flow Hedging - Hedges of Forecasted Foreign Currency Revenue
The Company transacts business in U.S. Dollars and in various other currencies. The Company may use foreign exchange or forward contracts to hedge certain cash flow exposures resulting from changes in these foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities of up to twelve months. The Company enters into these foreign exchange contracts to hedge a portion of its forecasted foreign currency denominated revenue in the normal course of business, and accordingly, they are not speculative in nature.
As of March 31, 2025, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of €50.4 million into dollars.
Note 11. Equity
a. Share capital
The Company's issued share capital is composed of ordinary shares, NIS 0.01 par value per share ("ordinary shares"). Ordinary shares confer upon their holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends if declared. The Company's ordinary shares are traded in the United States on the Nasdaq Global Select Market under the ticker symbol "SSYS". As of March 31, 2025 and December 31, 2024, there were 72,657 thousand ordinary shares and 71,982 thousand ordinary shares issued and 72,391 thousand ordinary shares and 71,716 thousand ordinary shares outstanding, net of treasury shares, respectively. The change in the issued and outstanding ordinary shares during the three months ended March 31, 2025 was attributable to exercises of share options and RSUs under the Company's share-based compensation plans. During the three months ended March 31, 2025, the Company's board of directors increased the reserve pool under the Company's 2022 Share Incentive Plan by 2.7 million shares.
16
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
b. Share Repurchase Program and Treasury Stock
On September 16, 2024, the Company's Board of Directors authorized a share repurchase program that provides for the repurchase of up to $50 million of the Company's ordinary shares, from time to time. Under the share repurchase program, the Company may effect repurchases by way of a variety of methods, including open market purchases, privately negotiated transactions or otherwise, all in accordance with U.S. securities laws and regulations, including Rule 10b-18 under the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company may also, from time to time, enter into plans that are compliant with Rule 10b5-1 of the Exchange Act to facilitate repurchases of its ordinary shares under the Board authorization. The repurchase program does not obligate the Company to acquire any particular number or value of ordinary shares, and the repurchase program may be suspended or discontinued at any time at the Company's discretion. In accordance with Section 7C of the Israeli Companies Regulations, the share repurchase program became effective 30 days after notice of Company's board of directors' adoption of the repurchase program was provided to the Company's material creditors and secured creditors.
During the year ended December 31, 2024, the Company repurchased 266 thousand ordinary shares for approximately $2.0 million at a weighted average cost of $7.50 per share.
c. Share-based compensation program
Share-based compensation expenses for equity-classified share options, restricted share units ("RSUs") and performance-based restricted share units ("PSUs") were allocated as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
2025
|
|
2024
|
|
|
U.S $ in thousands
|
Cost of revenues
|
|
$
|
708
|
|
|
$
|
952
|
|
Research and development, net
|
|
1,240
|
|
|
2,131
|
|
Selling, general and administrative
|
|
4,265
|
|
|
5,566
|
|
Total stock-based compensation expenses
|
|
$
|
6,213
|
|
|
$
|
8,649
|
|
A summary of the Company's share option activity for the three months ended March 31, 2025 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Options
|
|
Weighted Average Exercise Price
|
Options outstanding as of January 1, 2025
|
|
1,250,004
|
|
|
19.18
|
|
Forfeited
|
|
(37,619)
|
|
|
19.66
|
|
Options outstanding as of March 31, 2025
|
|
1,212,385
|
|
|
19.17
|
|
Options exercisable as of March 31, 2025
|
|
1,017,312
|
|
|
20.00
|
|
As of March 31, 2025, the unrecognized compensation cost of $0.2 million related to all unvested, equity-classified share options is expected to be recognized as an expense over a weighted-average period of 0.81 years.
17
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
A summary of the Company's RSUs and PSUs activity for the three months ended March 31, 2025 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of RSUs and PSUs
|
|
Weighted Average Grant Date Fair Value
|
Unvested as of January 1, 2025
|
|
3,945,120
|
|
|
13.67
|
|
Granted
|
|
2,010,477
|
|
|
10.43
|
|
Vested
|
|
(662,640)
|
|
|
17.36
|
|
Forfeited
|
|
(177,182)
|
|
|
17.13
|
|
Unvested as of March 31, 2025
|
|
5,115,775
|
|
|
11.80
|
|
The fair value of RSUs and PSUs is determined based on the quoted price of the Company's ordinary shares on the date of the grant.
As of March 31, 2025, the unrecognized compensation cost of $54.0 million related to all unvested, equity-classified RSUs and PSUs is expected to be recognized as expense over a weighted-average period of 2.93 years.
d. Accumulated other comprehensive loss
The following tables present the changes in the components of accumulated other comprehensive income (loss), net of taxes, for the three months ended March 31, 2025 and 2024, respectively:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31, 2025
|
|
Net Unrealized Gain (Loss) on Cash Flow Hedges
|
|
Foreign Currency Translation Adjustments
|
|
Total
|
|
U.S. $ in thousands
|
Balance as of January 1, 2025
|
$
|
4,907
|
|
|
$
|
(12,938)
|
|
|
$
|
(8,031)
|
|
Other comprehensive income (loss) before reclassifications
|
(1,778)
|
|
|
1,726
|
|
|
(52)
|
|
Amounts reclassified from accumulated other comprehensive loss
|
(1,257)
|
|
|
-
|
|
|
(1,257)
|
|
Other comprehensive income (loss)
|
(3,035)
|
|
|
1,726
|
|
|
(1,309)
|
|
Balance as of March 31, 2025
|
$
|
1,872
|
|
|
$
|
(11,212)
|
|
|
$
|
(9,340)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31, 2024
|
|
Net Unrealized Gain (Loss) on Cash Flow Hedges
|
|
Foreign Currency Translation Adjustments
|
|
Total
|
|
U.S. $ in thousands
|
Balance as of January 1, 2024
|
$
|
1,790
|
|
|
$
|
(8,869)
|
|
|
$
|
(7,079)
|
|
Other comprehensive income (loss) before reclassifications
|
1,493
|
|
|
(2,186)
|
|
|
(693)
|
|
Amounts reclassified from accumulated other comprehensive loss
|
(811)
|
|
|
-
|
|
|
(811)
|
|
Other comprehensive income (loss)
|
682
|
|
|
(2,186)
|
|
|
(1,504)
|
|
Balance as of March 31, 2024
|
$
|
2,472
|
|
|
$
|
(11,055)
|
|
|
$
|
(8,583)
|
|
18
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Note 12. Contingencies
Legal proceedings
Ordinary course litigation
The Company is a party to various legal proceedings from time to time, the outcome of which, in the opinion of management, will not have a significant effect on the financial position, profitability or cash flows of the Company.
Note 13. Segment
The Company's chief operating decision maker ("CODM") manages the Company's business activities as a single operating and reportable segment and reviews financial information prepared on a consolidated basis. The Company's reportable segment generates revenues through the sale of its 3D printing systems, related services and consumables and by providing additive manufacturing ("AM") solutions. The CODM reviews and utilizes budget-to-actual variances of profit measures and functional expenses (cost of revenues, research and development, net, and selling, general and administrative), at the consolidated level to manage the Company's operations and to make key operating decisions. Other segment items included in consolidated net income are financial income, net and income tax expenses, which are reflected in the consolidated statements of operations and comprehensive loss.
Note 14. Restructuring costs
In August 2024, the Company announced cost savings initiatives (the "Restructuring Plan") that includes a global workforce reduction. As a result of this restructuring plan, the Company expects $40 million of aggregate annualized cost savings. The Company substantially completed the implementation of this initiative by the end of 2024.
During the three months ended March 31, 2025 the Company recorded the following activity related to the 2024 Restructuring Plan in accrued expenses and other current liabilities on the balance sheet (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2025
|
|
|
(U.S. $ in thousands)
|
Accrued expenses and other current liabilities as of January 1, 2025
|
|
$
|
3,859
|
|
Restructuring charges and exchange rate impact
|
|
386
|
|
Cash payments
|
|
(704)
|
|
Accrued expenses and other current liabilities as of March 31, 2025
|
|
$
|
3,541
|
|
During the three months ended March 31, 2025 the Company recognized the following restructuring charges, which were expensed as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2025
|
|
|
(U.S. $ in thousands)
|
Research and development, net
|
|
$
|
256
|
|
Selling, general and administrative
|
|
20
|
|
Interest and other (expense) income, net
|
|
110
|
|
Total restructuring charges
|
|
$
|
386
|
|
19
STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
Note 15. Subsequent events
Closing of PIPE Transaction
On April 8, 2025, The Company completed its previously-reported private investment in public equity transaction (the "PIPE") pursuant to which FF6-SSYS, Limited Partnership ("FF6-SSYS"), an affiliate of Fortissimo Capital, an Israeli private equity fund (together with its affiliates, collectively, "Fortissimo") invested $120 million in Stratasys and acquired 11,650,485 newly-issued ordinary shares of the Company at a price of $10.30 per share.
20